New England Journal of Medicine· 2020Q1· Clinical trial

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Fernando P. Polack, Stephen J. Thomas, Nicholas Kitchin, Judith Absalon et al.

15,595citations
Q1SCImago
2020year

Short summary

The BNT162b2 mRNA vaccine candidate demonstrated 95% efficacy in preventing Covid-19 after two doses, with a similar safety profile to other viral vaccines.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Infectious Diseases

Infectious DiseasesMedicine